CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

NCT03605927 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Graft-versus-host-disease
GVHD
GVHD, Acute

Interventions

DRUG: BMS-986004
DRUG: Sirolimus
DRUG: Tacrolimus

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]